Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
1.4K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

9.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.2K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

14.1K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
14.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Prospective Multicenter Assessment of the Accuracy and Safety of the Yuwell CT3 Real-Time Continuous Glucose Monitoring System in Patients With Diabetes Over 14 Days.

Journal of diabetes·2026
Same author

Performance and Safety of a 15-Day Real-Time Continuous Glucose Monitoring System in Chinese Adults With Diabetes: A Multicenter Trial.

Journal of diabetes science and technology·2026
Same author

From "Deqi" to Sng: Can the sensations of acupuncture advance from terminological consensus to standardization?

Journal of the Formosan Medical Association = Taiwan yi zhi·2026
Same author

Thermoneutrality Reveals True Cardiac Adaptations to Exercise, Disease, and Aging in Male Mice.

Acta physiologica (Oxford, England)·2026
Same author

Neuroprotective role of Faecalibacterium prausnitzii-derived butyrate in diabetic gastrointestinal autonomic neuropathy.

Journal of genetics and genomics = Yi chuan xue bao·2026
Same author

Breaking the interfacial stability bottleneck of Zn anode via biomass carbon dots-enabled endogenous hybrid interphase.

Journal of colloid and interface science·2026

Related Experiment Video

Updated: May 5, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

2.3K

Ginkgetin: A Promising Multitarget Agent for Diverse Diseases.

Zhitong Sun1, Zhijian Rao2,3, Yibing Lu1

  • 1College of Physical Education, Shanghai University, Shanghai 200444, China.

Biomolecules
|May 4, 2026
PubMed
Summary

Ginkgetin (GK), a biflavonoid from Ginkgo biloba, shows broad preclinical therapeutic potential due to its unique structure and multitarget actions. Further clinical studies are needed to overcome bioavailability challenges for human applications.

Keywords:
biflavonoidginkgetinmolecular mechanismsmultitarget pharmacologypreclinical studiestherapeutic potential

Related Experiment Videos

Last Updated: May 5, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

2.3K

Area of Science:

  • Natural Product Chemistry
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Ginkgetin (GK) is a biflavonoid isolated from Ginkgo biloba, structurally distinct due to its 3'-8″-linked biflavone subclass.
  • Its unique dimeric architecture enhances membrane permeability and allows for multitarget engagement.

Purpose of the Study:

  • To systematically review the chemical characteristics, pharmacological activities, and molecular mechanisms of Ginkgetin (GK).
  • To emphasize GK's multitarget actions and therapeutic potential across various disease systems.
  • To discuss limitations and future perspectives for GK's clinical translation.

Main Methods:

  • Literature review of preclinical studies on Ginkgetin (GK).
  • Analysis of GK's chemical structure, pharmacological effects, and molecular targets.
  • Synthesis of information on therapeutic potential and challenges in clinical translation.

Main Results:

  • GK exhibits pleiotropic effects including anti-inflammatory, antioxidant, anticancer, neuroprotective, and cardioprotective activities.
  • Mechanistically, GK modulates key signaling pathways like Nrf2/HO-1, NF-κB, JAK/STAT, MAPKs, AMPK/mTOR, PI3K/Akt, and cGAS-STING.
  • GK shows therapeutic potential in cancer, metabolic, cardiovascular, neurological, and musculoskeletal diseases, with emerging antibacterial properties.

Conclusions:

  • Ginkgetin (GK) possesses significant multitarget therapeutic potential demonstrated in preclinical studies.
  • Challenges in pharmacokinetics, bioavailability, and druggability currently limit its clinical translation.
  • Further research and rational development are needed to facilitate GK-based interventions in human medicine.